Blocking autophagy prevents bortezomib-induced NF-κB activation by reducing I-κBα degradation in lymphoma cells

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Jia, Li ^a   Gopinathan, Ganga ^a   Sukumar, Johanna T ^a   Gribben, John G ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CELL PROTEIN; CHLOROQUINE; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LC3 II PROTEIN; PROTEIN P62; UBIQUITINATED PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; I KAPPA B; NF KAPPAB INHIBITOR ALPHA; NF-KAPPAB INHIBITOR ALPHA; PROTEASOME; PYRAZINE DERIVATIVE; UBIQUITIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGOSOME; AUTOPHAGY; CANCER INHIBITION; CANCER RESISTANCE; CELL NUCLEUS TRANSPLANTATION; COMPLEX FORMATION; CONTROLLED STUDY; DRUG MECHANISM; ENDOPLASMIC RETICULUM STRESS; LARGE CELL LYMPHOMA; LYMPHOMA CELL; PHARMACOLOGICAL BLOCKING; PROTEIN DEGRADATION; PROTEIN DNA BINDING; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; TRANSCRIPTION INITIATION; UBIQUITINATION; UPREGULATION; ACTIVE TRANSPORT; CELL DEATH; CHEMISTRY; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; LYMPHOMA; METABOLISM; METHODOLOGY; MITOCHONDRION; TUMOR CELL LINE;

ACTIVE TRANSPORT, CELL NUCLEUS; ANTINEOPLASTIC AGENTS; AUTOPHAGY; BORONIC ACIDS; CELL DEATH; CELL LINE, TUMOR; FLOW CYTOMETRY; GENE EXPRESSION; HUMANS; I-KAPPA B PROTEINS; LYMPHOMA; MITOCHONDRIA; NF-KAPPA B; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; UBIQUITIN;

EID: 84857668451     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0032584     Document Type: Article

References (45)

1. Chauhan D, Li G, Podar K, Hideshima T, Shringarpure R, et al. (2004) The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance. Blood 103: 3158-3166.
2. Mitsiades N, Mitsiades CS, Richardson PG, Poulaki V, Tai YT, et al. (2003) The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 101: 2377-2380.
3. Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, et al. (2001) The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61: 3071-3076.
4. Chauhan D, Singh A, Brahmandam M, Podar K, Hideshima T, et al. (2008) Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma. Blood 111: 1654-1664.
5. Ma MH, Yang HH, Parker K, Manyak S, Friedman JM, et al. (2003) The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res 9: 1136-1144.
6. Liu FT, Agrawal SG, Gribben JG, Ye H, Du MQ, et al. (2008) Bortezomib blocks Bax degradation in malignant B cells during treatment with TRAIL. Blood 111: 2797-2805.
7. Yang Y, Ikezoe T, Saito T, Kobayashi M, Koeffler HP, et al. (2004) Proteasome inhibitor PS-341 induces growth arrest and apoptosis of non-small cell lung cancer cells via the JNK/c-Jun/AP-1 signaling. Cancer Sci 95: 176-180.
8. Lonial S, Boise LH, (2011) Farnesyl transferase inhibitors, autophagy, and proteasome inhibition: synergy for all the right reasons. Autophagy 7: 448-449.
9. David E, Kaufman JL, Flowers CR, Schafer-Hales K, Torre C, et al. (2010) Tipifarnib sensitizes cells to proteasome inhibition by blocking degradation of bortezomib-induced aggresomes. Blood 116: 5285-5288.
10. Catley L, Weisberg E, Kiziltepe T, Tai YT, Hideshima T, et al. (2006) Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood 108: 3441-3449.
11. Moscat J, Diaz-Meco MT, (2009) p62 at the crossroads of autophagy, apoptosis, and cancer. Cell 137: 1001-1004.
12. Fujita K, Maeda D, Xiao Q, Srinivasula SM, (2011) Nrf2-mediated induction of p62 controls Toll-like receptor-4-driven aggresome-like induced structure formation and autophagic degradation. Proc Natl Acad Sci U S A 108: 1427-1432.
13. Ding WX, Ni HM, Gao W, Chen X, Kang JH, et al. (2009) Oncogenic transformation confers a selective susceptibility to the combined suppression of the proteasome and autophagy. Mol Cancer Ther 8: 2036-2045.
14. Korolchuk VI, Mansilla A, Menzies FM, Rubinsztein DC, (2009) Autophagy inhibition compromises degradation of ubiquitin-proteasome pathway substrates. Mol Cell 33: 517-527.
15. Perkins ND, (2007) Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell Biol 8: 49-62.
16. Hideshima T, Ikeda H, Chauhan D, Okawa Y, Raje N, et al. (2009) Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood 114: 1046-1052.
17. Sarosiek KA, Cavallin LE, Bhatt S, Toomey NL, Natkunam Y, et al. (2010) Efficacy of bortezomib in a direct xenograft model of primary effusion lymphoma. Proc Natl Acad Sci U S A 107: 13069-13074.
18. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, et al. (2002) The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346: 1937-1947.
19. Davis RE, Brown KD, Siebenlist U, Staudt LM, (2001) Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 194: 1861-1874.
20. Dunleavy K, Pittaluga S, Czuczman MS, Dave SS, Wright G, et al. (2009) Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood 113: 6069-6076.
21. Dasmahapatra G, Lembersky D, Kramer L, Fisher R, Friedberg J, et al. (2010) The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo. Blood.
22. Maclean KH, Dorsey FC, Cleveland JL, Kastan MB, (2008) Targeting lysosomal degradation induces p53-dependent cell death and prevents cancer in mouse models of lymphomagenesis. J Clin Invest 118: 79-88.
23. Deng J, Carlson N, Takeyama K, Dal Cin P, Shipp M, et al. (2007) BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. Cancer Cell 12: 171-185.
24. Culpin RE, Proctor SJ, Angus B, Crosier S, Anderson JJ, et al. (2010) A 9 series microRNA signature differentiates between germinal centre and activated B-cell-like diffuse large B-cell lymphoma cell lines. Int J Oncol 37: 367-376.
25. Liu FT, Agrawal SG, Movasaghi Z, Wyatt PB, Rehman IU, et al. (2008) Dietary flavonoids inhibit the anticancer effects of the proteasome inhibitor bortezomib. Blood 112: 3835-3846.
26. Jia L, Allen PD, Macey MG, Grahn MF, Newland AC, et al. (1997) Mitochondrial electron transport chain activity, but not ATP synthesis, is required for drug-induced apoptosis in human leukaemic cells: a possible novel mechanism of regulating drug resistance. Br J Haematol 98: 686-698.
27. Wehbe-Janek H, Shi Q, Kearney CM, (2007) Cordycepin/Hydroxyurea synergy allows low dosage efficacy of cordycepin in MOLT-4 leukemia cells. Anticancer Res 27: 3143-3146.
28. Chauhan D, Li G, Shringarpure R, Podar K, Ohtake Y, et al. (2003) Blockade of Hsp27 overcomes Bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells. Cancer Res 63: 6174-6177.
29. Ding WX, Ni HM, Gao W, Yoshimori T, Stolz DB, et al. (2007) Linking of autophagy to ubiquitin-proteasome system is important for the regulation of endoplasmic reticulum stress and cell viability. Am J Pathol 171: 513-524.
30. Kraft C, Peter M, Hofmann K, (2010) Selective autophagy: ubiquitin-mediated recognition and beyond. Nat Cell Biol 12: 836-841.
31. Pankiv S, Clausen TH, Lamark T, Brech A, Bruun JA, et al. (2007) p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy. J Biol Chem 282: 24131-24145.
32. Oyadomari S, Mori M, (2004) Roles of CHOP/GADD153 in endoplasmic reticulum stress. Cell Death Differ 11: 381-389.
33. Ciani B, Layfield R, Cavey JR, Sheppard PW, Searle MS, (2003) Structure of the ubiquitin-associated domain of p62 (SQSTM1) and implications for mutations that cause Paget's disease of bone. J Biol Chem 278: 37409-37412.
34. Kirkin V, McEwan DG, Novak I, Dikic I, (2009) A role for ubiquitin in selective autophagy. Mol Cell 34: 259-269.
35. Kroll M, Conconi M, Desterro MJ, Marin A, Thomas D, et al. (1997) The carboxy-terminus of I kappaB alpha determines susceptibility to degradation by the catalytic core of the proteasome. Oncogene 15: 1841-1850.
36. Li C, Chen S, Yue P, Deng X, Lonial S, et al. (2010) Proteasome inhibitor PS-341 (bortezomib) induces calpain-dependent IkappaB(alpha) degradation. J Biol Chem 285: 16096-16104.
37. Pahl HL, (1999) Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 18: 6853-6866.
38. Palombella VJ, Rando OJ, Goldberg AL, Maniatis T, (1994) The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell 78: 773-785.
39. Adams J, Kauffman M, (2004) Development of the proteasome inhibitor Velcade (Bortezomib). Cancer Invest 22: 304-311.
40. Richardson PG, Hideshima T, Anderson KC, (2003) Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers. Cancer Control 10: 361-369.
41. Markovina S, Callander NS, O'Connor SL, Kim J, Werndli JE, et al. (2008) Bortezomib-resistant nuclear factor-kappaB activity in multiple myeloma cells. Mol Cancer Res 6: 1356-1364.
42. Yang DT, Young KH, Kahl BS, Markovina S, Miyamoto S, (2008) Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma. Mol Cancer 7: 40.
43. Levine B, Kroemer G, (2008) Autophagy in the pathogenesis of disease. Cell 132: 27-42.
44. Gamerdinger M, Kaya AM, Wolfrum U, Clement AM, Behl C, (2011) BAG3 mediates chaperone-based aggresome-targeting and selective autophagy of misfolded proteins. EMBO Rep 12: 149-156.
45. Amaravadi RK, Yu D, Lum JJ, Bui T, Christophorou MA, et al. (2007) Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. J Clin Invest 117: 326-336.